• OncologyTube Cancer Articles, News and Videos

      Site: OncologyTube Cancer Articles, News and Videos

    • Search in
    • Categories
    • Tags
    • Date within
    • Views
    • 0
      • Portuguese
      • Spanish
      • Italian
      • Greek (Greece)
      • Sinhala
      • Polish
      • Arabic (Saudi Arabia)
      • Swedish (Sweden)
      • Portuguese (Brazil)
      • Hindi (India)
      • English (Australia)
      • Hebrew (Israel)
      • Czech
      • Hungarian (Hungary)
      • Chinese
      • Turkish
      • Japanese (Japan)
      • Dutch
      • French
      • German
      • Chinese (Traditional Han, Taiwan)
      • Korean (South Korea)
      • Thai
      • Spanish (Chile)
      • English (United States)
      • Russian
      • Danish (Denmark)
  • Home
  • Trending

  • Login

  • Quick Links
  • Self Serve Advertising Portal - Buy Ads Now! No Contracts!
  • How To Self Record An Interview and Presentations
  • Schedule A Remote Interview!
  • Check Out Our Blog
  • Advertising Specifications
  • Publisher Calendar

  • Mobile
  • Connect Mobile App

  • Audio and Video
  • Videos
  • Audio

  • Channels
  • Browse Channels

  • Categories
  • Acute Lymphoblastic Leukemia 5616
  • Acute Myelogenous Leukemia 277
  • Bladder 111
  • Bone Metastases 7
  • Brain 90
  • Breast 585
  • Business Management 5
  • Cervical 18
  • Chronic Lymphocytic Leukemia 216
  • Chronic Myelogenous Leukemia 54
  • Colorectal 184
  • Conference Coverage 1
  • COVID-19 43
  • Gastrointestinal 182
  • General 350
  • Genitourinary 6
  • Head and Neck 125
  • Help 3
  • Hematologic Malignancies 213
  • Hodgkin Lymphoma 34
  • Imaging 2
  • Immunotherapy 182
  • Kidney 399
  • Liver 41
  • Lung 108
  • Lymphoma 247
  • Melanoma and Skin 111
  • Multiple Myeloma 545
  • Myeloproliferative Disease 41
  • News 152
  • Non-Hodgkin Lymphoma 82
  • Non-Small Cell Lung Cancer 638
  • Other 525
  • Ovarian 67
  • Pancreatic 112
  • Patient Resources 51
  • Pediatric 7
  • Prostate 306
  • Sarcoma 15
  • Sickle Cell 22
  • Small Cell Lung Cancer 83
  • Supportive Care 51
  • Testicular 3
  • Urology 16
  • Uterine 10

  • Install
  • Play a Link
  • About
  • Contact
Podcast - Bradley Monk, MD @ArizonaOncology @GOG #ESMO21 #KEYNOTE826 #MetastaticCervicalCancer #Cancer #Research Presidential Symposium: KEYNOTE-826
0:06:40

Podcast - Bradley Monk, MD @ArizonaOncology @GOG #ESMO21 #KEYNOTE826 #MetastaticCervicalCancer #Cancer #Research Pres...

Bradley Monk, MD, FACOG, FACS, Gynecologic Oncologist, Arizona Oncology speaks about the ESMO 2021 Abstract #LBA2, Presidential Symposium: KEYNOTE-826: A Randomized, Double-Blind, Phase 3 Study of Pembrolizumab + Chemotherapy vs Placebo + Chemotherapy for First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer.

Link to Abstract:
https://oncologypro.esmo.org/meeting-resources/esmo-asia-congress-2019/keynote-826-a-phase-iii-randomized-study-of-chemotherapy-with-or-without-pembrolizumab-for-first-line-treatment-of-persistent-recurrent-or-metas


265TiP Abstract:

Background:

Patients with advanced cervical cancer have a significant chance of death and a poor prognosis. Although adding the anti-VEGF agent bevacizumab to platinum- and taxane-based chemotherapy (CT) is associated with a modest OS benefit compared to CT alone (median OS, 16.8 vs 13.3 mo; hazard ratio, 0.77, 95 percent CI, 0.62-0.95; P = 0.007; Tewari et al. Lancet. 2017), VEGF has emerged as a therapeutic target for these patients. The PD-1 inhibitor pembrolizumab was granted accelerated approval by the US FDA for patients with PD-L1–positive (combined positive score [CPS] of > 1) cervical cancer who had progressed during or after treatment based on an ORR of 14.3 percent (95 percent CI, 7.4-24.1) in the cervical cancer cohort of KEYNOTE-158 (Chung et al. J Clin Oncol. 2019). KEYNOTE-826 (NCT03635567) is a phase 3 randomized, double-blind, international trial evaluating the effectiveness and acceptability of CT in the first-line context with or without pembrolizumab and/or bevacizumab.

Design of the experiment:

Every three weeks, eligible patients with recurrent, persistent, or metastatic cervical cancer who have not previously had CT in a recurrent or metastatic context and are not susceptible to curative therapy will be randomized 1:1 to CT + pembrolizumab 200 mg or placebo. Before randomization, the investigator will choose the CT regimen (paclitaxel 175 mg/m2 + cisplatin 50 mg/m2 or carboplatin AUC 5, with or without bevacizumab 15 mg/kg). Metastasis status at diagnosis, planned bevacizumab usage (yes/no), and tumor PD-L1 CPS (1, 1 to 10, or 10) will all be used to stratify patients. Treatment will last 35 cycles (two years) or until illness progression, intolerable toxicity, or patient withdrawal. PFS per RECIST v1.1 (evaluated by blinded independent central review) and OS are the primary objectives. ORR, the durability of response, 12-month PFS, patient-reported quality of life, and safety are secondary goals. Enrollment is open right now.

Clinical trial identification
NCT03635567.

57 Views
2 years Ago
ESMO
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

Cervical

Triapine and Its Role in Advanced Cervical and Vaginal Cancer
Triapine and Its Role in Advanced Cervical and Vaginal Cancer
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
19 Views
Oncology Conferences
3 months Ago
Triapine Incorporated with CRT: Phase 3 NRG-GY006 Trail Results
0:14:50
Triapine Incorporated with CRT: Phase 3 NRG-GY006 Trail Results
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
50 Views
Oncology Conferences
3 months Ago
Podcast - Mansoor Raza Mirza, MD @uni_copenhagen @UCPH_health #KEYNOTE826 #FDAApproval #CervicalCancer #Cancer #Research FDA Approves Pembrolizumab Plus Chemo as First-Line Therapy for Ad...
0:13:40
Podcast - Mansoor Raza Mirza, MD @uni_copenhagen @UCPH_health #KEYNOTE826 #FDAApproval #CervicalCancer #Cancer #Resea...
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
24 Views
Cancer News
1 year Ago
Mansoor Raza Mirza, MD @uni_copenhagen @UCPH_health #KEYNOTE826 #FDAApproval #CervicalCancer #Cancer #Research FDA Approves Pembrolizumab Plus Chemo as First-Line Therapy for Advanced, Re...
0:13:40
Mansoor Raza Mirza, MD @uni_copenhagen @UCPH_health #KEYNOTE826 #FDAApproval #CervicalCancer #Cancer #Research FDA Ap...
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
86 Views
Cancer News
1 year Ago
Podcast - Ignace B. Vergote, MD, PhD @UZLeuven #CervicalCancer #Cancer #Research 723MO - TV + Carbo In 1L Or + Pembro In Previously Treated  r/mCC
0:19:01
Podcast - Ignace B. Vergote, MD, PhD @UZLeuven #CervicalCancer #Cancer #Research 723MO - TV + Carbo In 1L Or + Pembro...
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
17 Views
ESMO
1 year Ago
Ignace B. Vergote, MD, PhD @UZLeuven #CervicalCancer #Cancer #Research 723MO - TV + Carbo In 1L Or + Pembro In Previously Treated  r/mCC
0:19:01
Ignace B. Vergote, MD, PhD @UZLeuven #CervicalCancer #Cancer #Research 723MO - TV + Carbo In 1L Or + Pembro In Previo...
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
60 Views
ESMO
1 year Ago
Podcast - Bradley Monk, MD @ArizonaOncology @GOG #ESMO21 #KEYNOTE826 #MetastaticCervicalCancer #Cancer #Research Presidential Symposium: KEYNOTE-826
0:06:40
Podcast - Bradley Monk, MD @ArizonaOncology @GOG #ESMO21 #KEYNOTE826 #MetastaticCervicalCancer #Cancer #Research Pres...
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
57 Views
ESMO
2 years Ago
Bradley Monk, MD @ArizonaOncology @GOG #ESMO21 #KEYNOTE826 #MetastaticCervicalCancer #Cancer #Research Presidential Symposium: KEYNOTE-826
0:06:40
Bradley Monk, MD @ArizonaOncology @GOG #ESMO21 #KEYNOTE826 #MetastaticCervicalCancer #Cancer #Research Presidential S...
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
92 Views
ESMO
2 years Ago
Podcast - David M. O'Malley, MD @omalleygynonc @OhioStateMed @OSUCCC_James #ESMO21 #OvarianCancer #Cancer #Research Single-agent Anti-PD-1 Balstilimab Or In Combination With Anti-CTLA-4 ...
0:11:55
Podcast - David M. O'Malley, MD @omalleygynonc @OhioStateMed @OSUCCC_James #ESMO21 #OvarianCancer #Cancer #Research S...
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
25 Views
ESMO
2 years Ago
David M. O'Malley, MD @omalleygynonc @OhioStateMed @OSUCCC_James #ESMO21 #OvarianCancer #Cancer #Research Single-agent Anti-PD-1 Balstilimab Or In Combination With Anti-CTLA-4 Zalifrelimab
0:11:55
David M. O'Malley, MD @omalleygynonc @OhioStateMed @OSUCCC_James #ESMO21 #OvarianCancer #Cancer #Research Single-agen...
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
23 Views
ESMO
2 years Ago
Podcast - David M. O'Malley, MD @omalleygynonc @OhioStateMed @OSUCCC_James @GOG @GOGPartners #ESMO21 #CervicalCancer #Cancer #Research - Balstilimab in combination with zalifrelimab
0:11:55
Podcast - David M. O'Malley, MD @omalleygynonc @OhioStateMed @OSUCCC_James @GOG @GOGPartners #ESMO21 #CervicalCancer ...
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
218 Views
ESMO
2 years Ago
David M. O'Malley, MD @omalleygynonc @OhioStateMed @OSUCCC_James @GOG @GOGPartners #ESMO21 #CervicalCancer #Cancer #Research - Balstilimab in combination with zalifrelimab
0:11:55
David M. O'Malley, MD @omalleygynonc @OhioStateMed @OSUCCC_James @GOG @GOGPartners #ESMO21 #CervicalCancer #Cancer #R...
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
78 Views
ESMO
2 years Ago

comments@oncologytube.com Copyright 2023 Medicus Networks, Inc. 45121 Morgan Heights Rd. Temecula, CA 92592 - 1 (951) 944-2173